Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Rewriting Life

Merck Invests in RNA Startup to Target Cancer

If it works, mRNA therapy could provide a simple way to create customized cancer vaccines.

Pharmaceutical giant Merck has announced a $200 million licensing agreement with Moderna Therapeutics, a startup based in Cambridge, Massachusetts, that is developing therapies based on RNA. Merck wants to combine its expertise in cancer immunotherapy with Moderna’s personalized cancer vaccines so that the two treatments together can more effectively target cancer.

Moderna hopes to have its tailored cancer vaccines ready for clinical trials in 2017. The company’s novel therapeutics are essentially modified molecules of messenger RNA, or mRNA, which translates the genetic code of DNA into proteins. Rearranging the nucleotides, or letters, in mRNA allows Moderna to create antibodies and other proteins that are useful in therapies for a wide range of conditions.

Theoretically, therapeutic mRNA should allow for the production of virtually any protein in the body. But if it sounds simple, there’s a reason it didn’t gain traction before. If straight mRNA is injected into the bloodstream, the body attacks it in an immune reaction, mistaking it for a virus. Moderna’s treatments overcome this challenge by swapping two of the mRNA letters for natural analogues that don’t trigger a viral immune response.

There are several other companies with similar mRNA-based therapeutics in the works. Shire announced work on using mRNA for a cystic fibrosis treatment in 2014, but it has remained silent on the development ever since. And the German biotech company Ethris is working on mRNA therapy for rare diseases.

Most of the competition in RNA therapy comes from companies working with a different technology: RNA interference, or RNAi, which can block the activity of naturally occurring mRNA. The idea is to halt the production of harmful proteins or the growth of cancer cells. Alnylam, also based in Cambridge, Massachusetts, has two RNAi therapies in late-stage human trials and several more in early clinical testing.

Be the leader your company needs. Implement ethical AI.
Join us at EmTech Digital 2019.

Register now
More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Plus.
  • Insider Plus {! insider.prices.plus !}*

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    Print + Digital Magazine (6 bi-monthly issues)

    Unlimited online access including all articles, multimedia, and more

    The Download newsletter with top tech stories delivered daily to your inbox

    Technology Review PDF magazine archive, including articles, images, and covers dating back to 1899

    10% Discount to MIT Technology Review events and MIT Press

    Ad-free website experience

/3
You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.